Therapeutic options for vancomycin-resistant enterococcal bacteremia

References

• Schleifer KH, Kilpper-Bälz R. Transfer of Streptococcus faecalis and Streptococcus faecium to the Genus Enterococcus nom. rev. as Enterococcus faecalis comb. nov. and Enterococcus faecium comb. nov. Int J Syst Evol Microbiol 1984;34(1):31-4
   Google Scholar
• Teixeira LM, Carvalho SMG, Facklam RR. Enterococcus. In: Murray PR, Baron EJ, Jorgensen JH, et al. editors. Manual of Clinical Microbiology. 9th edition. vol 2. ASM Press; Washington, DC: 2007
   Google Scholar
• Agudelo Higuita NI, Huycke MM. Enterococcal Disease, Epidemiology, and Implications for Treatment. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: From Commensals to Leading Causes of Drug Resistant Infection. Massachusetts Eye and Ear Infirmary; Boston: 2014
   Google Scholar
• Chenoweth C, Schaberg D. The epidemiology of enterococci. Eur J Clin Microbiol Infect Dis 1990;9(2):80-9
   PubMed Web of Science ®Google Scholar
• Lebreton F, Le Bras F, Reffuveille F, et al. Galleria mellonella as a model for studying Enterococcus faecium host persistence. J Mol Microbiol Biotechnol 2011;21(3-4):191-6
   PubMedGoogle Scholar
• Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 2012;10(4):266-78
   PubMed Web of Science ®Google Scholar
• Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? J Antimicrob Chemother 2013;68(4):731-42
   PubMed Web of Science ®Google Scholar
• Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006;42(Suppl 1):S25-34
   PubMedGoogle Scholar
• Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989;8(11):943-50
   PubMed Web of Science ®Google Scholar
• Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13(4):686-707
   PubMed Web of Science ®Google Scholar
• Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319(3):157-61
   PubMed Web of Science ®Google Scholar
• Arthur M, Molinas C, Depardieu F, Courvalin P. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 1993;175(1):117-27
   PubMedGoogle Scholar
• Arthur M, Depardieu F, Molinas C, et al. The vanZ gene of Tn1546 from Enterococcus faecium BM4147 confers resistance to teicoplanin. Gene 1995;154(1):87-92
   PubMedGoogle Scholar
• Baptista M, Depardieu F, Courvalin P, Arthur M. Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis. Antimicrob Agents Chemother 1996;40(10):2291-5
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Nosocomial Enterococci Resistant to Vancomycin – United States, 1989-1993. MMWR 1993;42(30):597-9
   PubMedGoogle Scholar
• Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1(8575-6):57-8
   PubMed Web of Science ®Google Scholar
• Frieden TR, Munsiff SS, Low DE, et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993;342(8863):76-9
   PubMed Web of Science ®Google Scholar
• Van der Auwera P, Pensart N, Korten V, et al. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996;173(5):1129-36
   PubMed Web of Science ®Google Scholar
• Bates J, Jordens Z, Selkon JB. Evidence for an animal origin of vancomycin-resistant enterococci. Lancet 1993;342(8869):490-1
   PubMed Web of Science ®Google Scholar
• Descheemaeker PR, Chapelle S, Devriese LA, et al. Comparison of glycopeptide-resistant Enterococcus faecium isolates and glycopeptide resistance genes of human and animal origins. Antimicrob Agents Chemother 1999;43(8):2032-7
   PubMedGoogle Scholar
• Bager F, Aarestrup FM, Madsen M, Wegener HC. Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin. Microb Drug Resist 1999;5(1):53-6
   PubMedGoogle Scholar
• Klare I, Badstubner D, Konstabel C, et al. Decreased incidence of VanA-type vancomycin-resistant enterococci isolated from poultry meat and from fecal samples of humans in the community after discontinuation of avoparcin usage in animal husbandry. Microb Drug Resist 1999;5(1):45-52
   PubMed Web of Science ®Google Scholar
• Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990;3(1):46-65
   PubMed Web of Science ®Google Scholar
• Grayson ML, Eliopoulos GM, Wennersten CB, et al. Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother 1991;35(11):2180-4
   PubMed Web of Science ®Google Scholar
• Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29(11):996-1011
   PubMed Web of Science ®Google Scholar
• Jans B, Schoevaerdts D, Huang TD, et al. Epidemiology of multidrug-resistant microorganisms among nursing home residents in Belgium. PLoS One 2013;8(5):e64908
   Google Scholar
• Jones ME, Draghi DC, Thornsberry C, et al. Emerging resistance among bacterial pathogens in the intensive care unit–a European and North American Surveillance study. 2000-2002. Ann Clin Microbiol Antimicrob 2004;3:14
   PubMedGoogle Scholar
• Meyer E, Gastmeier P, Deja M, Schwab F. Antibiotic consumption and resistance: data from Europe and Germany. Int J Med Microbiol 2013;303(6-7):388-95
   PubMedGoogle Scholar
• Willems RJ, Top J, van Santen M, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005;11(6):821-8
   PubMed Web of Science ®Google Scholar
• Ruiz-Garbajosa P, de Regt M, Bonten M, et al. High-density fecal Enterococcus faecium colonization in hospitalized patients is associated with the presence of the polyclonal subcluster CC17. Eur J Clin Microbiol Infect Dis 2012;31(4):519-22
   PubMedGoogle Scholar
• de Regt MJ, van der Wagen LE, Top J, et al. High acquisition and environmental contamination rates of CC17 ampicillin-resistant Enterococcus faecium in a Dutch hospital. J Antimicrob Chemother 2008;62(6):1401-6
   PubMedGoogle Scholar
• Fridkin SK, Edwards JR, Courval JM, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001;135(3):175-83
   PubMedGoogle Scholar
• Olivier CN, Blake RK, Steed LL, Salgado CD. Risk of vancomycin-resistant Enterococcus (VRE) bloodstream infection among patients colonized with VRE. Infect Control Hosp Epidemiol 2008;29(5):404-9
   PubMed Web of Science ®Google Scholar
• Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342(10):710-21
   PubMed Web of Science ®Google Scholar
• Montecalvo MA, Shay DK, Patel P, et al. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996;156(13):1458-62
   PubMedGoogle Scholar
• Ziakas PD, Pliakos EE, Zervou FN, et al. MRSA and VRE colonization in solid organ transplantation: a meta-analysis of published studies. Am J Transplant 2014;14(8):1887-94
   PubMed Web of Science ®Google Scholar
• Billington EO, Phang SH, Gregson DB, et al. Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study. Int J Infect Dis 2014;26:76-82
   PubMed Web of Science ®Google Scholar
• Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 2014;58(2):734-9
   PubMed Web of Science ®Google Scholar
• da Silva NS, Muniz VD, Estofolete CF, et al. Identification of temporal clusters and risk factors of bacteremia by nosocomial vancomycin-resistant enterococci. Am J Infect Control 2014;42(4):389-92
   PubMedGoogle Scholar
• Zyvox® (linezolid) [product information]. New York, NY: Pfizer, Inc; 2007
   Google Scholar
• Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004;39(7):1010-15
   PubMed Web of Science ®Google Scholar
• Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011;66(Suppl 4):iv7-iv15
   PubMed Web of Science ®Google Scholar
• Patel K, Kabir R, Ahmad S, Allen SL. Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus. J Oncol Pharm Pract 2014. [Epub ahead of print]
   Google Scholar
• Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003;36(2):159-68
   PubMed Web of Science ®Google Scholar
• Kraft S, Mackler E, Schlickman P, et al. Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer 2011;19(12):1969-74
   PubMedGoogle Scholar
• Lucet JC, Armand-Lefevre L, Laurichesse JJ, et al. Rapid control of an outbreak of vancomycin-resistant enterococci in a French university hospital. J Hosp Infect 2007;67(1):42-8
   PubMedGoogle Scholar
• El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis 2003;5(3):121-5
   PubMedGoogle Scholar
• Hogan HL, Hachem RY, Neuhauser M, et al. Clinical experience of linezolid in bone marrow transplantation patients. J Pharm Pract 2010;23(4):352-7
   PubMedGoogle Scholar
• King ST, Usery JB, Holloway K, et al. Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections. J Antimicrob Chemother 2011;66(11):2673-5
   PubMedGoogle Scholar
• Marshall SH, Donskey CJ, Hutton-Thomas R, et al. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002;46(10):3334-6
   PubMed Web of Science ®Google Scholar
• Mendes RE, Flamm RK, Hogan PA, et al. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States. Antimicrob Agents Chemother 2014;58(2):1243-7
   PubMedGoogle Scholar
• Pogue JM, Paterson DL, Pasculle AW, Potoski BA. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2007;28(12):1382-8
   PubMedGoogle Scholar
• McGregor JC, Hartung DM, Allen GP, et al. Risk factors associated with linezolid-nonsusceptible enterococcal infections. Am J Infect Control 2012;40(9):886-7
   PubMedGoogle Scholar
• Cubicin® (daptomycin) [product information]. Lexington, MA: Cubist Pharmaceuticals; 2010
   Google Scholar
• Patel R, Gallagher JC. Vancomycin-Resistant Enterococcal Bacteremia Pharmacotherapy. Ann Pharmacother 2014;49(1):69-85
   PubMedGoogle Scholar
• Muraih JK, Pearson A, Silverman J, Palmer M. Oligomerization of daptomycin on membranes. Biochim Biophys Acta 2011;1808(4):1154-60
   PubMed Web of Science ®Google Scholar
• Zhang T, Muraih JK, Tishbi N, et al. Cardiolipin prevents membrane translocation and permeabilization by daptomycin. J Biol Chem 2014;289(17):11584-91
   PubMed Web of Science ®Google Scholar
• Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47(8):2538-44
   PubMed Web of Science ®Google Scholar
• Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004;48(1):63-8
   PubMed Web of Science ®Google Scholar
• Hall AD, Steed ME, Arias CA, et al. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2012;56(6):3174-80
   PubMed Web of Science ®Google Scholar
• Schriever CA, Fernandez C, Rodvold KA, Danziger LH. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 2005;62(11):1145-58
   PubMedGoogle Scholar
• Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006;26(3):347-52
   PubMedGoogle Scholar
• Gallagher JC, Perez ME, Marino EA, et al. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 2009;29(7):792-9
   PubMedGoogle Scholar
• Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009;33(6):543-8
   PubMedGoogle Scholar
• Sakoulas G, Golan Y, Lamp KC, et al. Daptomycin in the treatment of bacteremia. Am J Med 2007;120(10 Suppl 1):S21-7
   PubMedGoogle Scholar
• Swaminathan S, Alangaden GJ. Treatment of resistant enterococcal urinary tract infections. Curr Infect Dis Rep 2010;12(6):455-64
   PubMedGoogle Scholar
• Fisher L, North D. Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections. Int J Antimicrob Agents 2009;33(5):493-4
   PubMedGoogle Scholar
• Anastasiou DM, Thorne GM, Luperchio SA, Alder JD. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 2006;28(5):385-8
   PubMedGoogle Scholar
• Palmer KL, Daniel A, Hardy C, et al. Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 2011;55(7):3345-56
   PubMedGoogle Scholar
• Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011;365(10):892-900
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011;52(2):228-34
   PubMed Web of Science ®Google Scholar
• Lapierre L, Mollet B, Germond JE. Regulation and adaptive evolution of lactose operon expression in Lactobacillus delbrueckii. J Bacteriol 2002;184(4):928-35
   PubMedGoogle Scholar
• Sader HS, Farrell DJ, Flamm RK, Jones RN. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). Int J Antimicrob Agents 2014;43(5):465-9
   PubMed Web of Science ®Google Scholar
• Kamboj M, Cohen N, Gilhuley K, et al. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol 2011;32(4):391-4
   PubMed Web of Science ®Google Scholar
• Judge T, Pogue JM, Marchaim D, et al. Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycin. Infect Control Hosp Epidemiol 2012;33(12):1250-4
   PubMedGoogle Scholar
• Fuller RE, Drew RH, Perfect JR. Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin. Pharmacotherapy 1996;16(4):584-92
   PubMedGoogle Scholar
• Malbruny B, Canu A, Bozdogan B, et al. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 2002;46(7):2200-7
   PubMedGoogle Scholar
• Synercid I.V.® (quinupristin/dalfopristin) [product information]. Bristol, TN: Monarch Pharmaceuticals; 2011
   Google Scholar
• Raad I, Hachem R, Hanna H. Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction. J Antimicrob Chemother 2004;53(6):1105-8
   PubMedGoogle Scholar
• Winston DJ, Emmanouilides C, Kroeber A, et al. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2000;30(5):790-7
   PubMedGoogle Scholar
• Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999;44(2):251-61
   PubMedGoogle Scholar
• Linden PK, Moellering RCJr, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001;33(11):1816-23
   PubMedGoogle Scholar
• Deshpande LM, Fritsche TR, Moet GJ, et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58(2):163-70
   PubMed Web of Science ®Google Scholar
• Smith DL, Johnson JA, Harris AD, et al. Assessing risks for a pre-emergent pathogen: virginiamycin use and the emergence of streptogramin resistance in Enterococcus faecium. The Lancet Infect Dis 2003;3(4):241-9
   PubMedGoogle Scholar
• Isnard C, Malbruny B, Leclercq R, Cattoir V. Genetic basis for in vitro and in vivo resistance to lincosamides, streptogramins A, and pleuromutilins (LSAP phenotype) in Enterococcus faecium. Antimicrob Agents Chemother 2013;57(9):4463-9
   PubMedGoogle Scholar
• Tygacil (tigecycline) [product information]. Philadelphia, PA: Wyeth Pharmaceuticals. 2011
   Google Scholar
• Pankey GA, Ashcraft DS. In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay. Diagn Microbiol Infect Dis 2009;64(3):300-4
   PubMed Web of Science ®Google Scholar
• Polidori M, Nuccorini A, Tascini C, et al. Vancomycin-resistant Enterococcus faecium (VRE) bacteremia in infective endocarditis successfully treated with combination daptomycin and tigecycline. J Chemother 2011;23(4):240-1
   PubMed Web of Science ®Google Scholar
• Whang DW, Miller LG, Partain NM, McKinnell JA. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother 2013;57(10):5013-18
   PubMed Web of Science ®Google Scholar
• King EA, McCoy D, Desai S, et al. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary? J Antimicrob Chemother 2011;66(9):2112-18
   PubMedGoogle Scholar
• Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011;31(6):527-36
   PubMed Web of Science ®Google Scholar
• Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother 2013;57(9):4190-6
   PubMed Web of Science ®Google Scholar
• Poutsiaka DD, Skiffington S, Miller KB, et al. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007;54(6):567-71
   PubMed Web of Science ®Google Scholar
• Kvirikadze N, Suseno M, Vescio T, et al. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scand J Infect Dis 2006;38(4):290-2
   PubMed Web of Science ®Google Scholar
• Hapnes N, Twomey A, Knowles S. Persistent vancomycin and high-level gentamicin-resistant Enterococcus faecium bacteremia and intra-aortic thrombus in an extremely low birth-weight infant. J Perinatol 2009;29(1):66-8
   PubMedGoogle Scholar
• Noskin GA, Siddiqui F, Stosor V, et al. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 1999;28(3):689-90
   PubMed Web of Science ®Google Scholar
• Wareham DW, Abbas H, Karcher AM, Das SS. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. J Infect 2006;52(4):300-4
   PubMed Web of Science ®Google Scholar
• Mave V, Garcia-Diaz J, Islam T, Hasbun R. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother 2009;64(1):175-80
   PubMedGoogle Scholar
• McKinnell JA, Patel M, Shirley RM, et al. Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol Infect 2011;139(9):1342-50
   PubMed Web of Science ®Google Scholar
• Crank CW, Scheetz MH, Brielmaier B, et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin Ther 2010;32(10):1713-19
   PubMedGoogle Scholar
• Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997;39(Suppl A):145-51
   PubMedGoogle Scholar
• Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 2008;46(1):30-6
   PubMed Web of Science ®Google Scholar
• Gray JW, Darbyshire PJ, Beath SV, et al. Experience with quinupristin/dalfopristin in treating infections with vancomycin-resistant Enterococcus faecium in children. Pediatr Infect Dis J 2000;19(3):234-8
   PubMedGoogle Scholar
• Koc Y, Snydman DR, Schenkein DS, Miller KB. Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. Bone Marrow Transplant 1998;22(2):207-9
   PubMedGoogle Scholar
• Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin. Ann Pharmacother 2004;38(6):989-91
   PubMed Web of Science ®Google Scholar
• Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004;53(4):646-9
   PubMed Web of Science ®Google Scholar
• Howe RA, Robson M, Oakhill A, et al. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcus. J Antimicrob Chemother 1997;40(1):144-5
   PubMedGoogle Scholar
• Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998;27(5):1259-65
   PubMedGoogle Scholar
• Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34(1):1-14
   PubMed Web of Science ®Google Scholar
• Hayakawa K, Martin ET, Gudur UM, et al. Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci. Antimicrob Agents Chemother 2014;58(7):3968-75
   PubMedGoogle Scholar
• Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008;52(12):4442-7
   PubMed Web of Science ®Google Scholar
• Schaadt R, Sweeney D, Shinabarger D, Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 2009;53(8):3236-9
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother 2009;63(4):713-15
   PubMedGoogle Scholar
• Rodriguez-Avial I, Culebras E, Betriu C, et al. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother 2012;67(1):167-9
   PubMed Web of Science ®Google Scholar
• Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother 2010;54(5):2063-9
   PubMed Web of Science ®Google Scholar
• Flanagan S, Minassian SL, Morris D, et al. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother 2014;58(11):6471-6
   PubMed Web of Science ®Google Scholar
• Ong V, Flanagan S, Fang E, et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos 2014;42(8):1275-84
   PubMed Web of Science ®Google Scholar
• Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. Jama 2013;309(6):559-69
   PubMed Web of Science ®Google Scholar
• De Anda C, Das A, Fang E. Efficacy and safety results from the ESTABLISH-2 ABSSSI study comparing IV and oral tedizolid phosphate and linezolid. Poster presented at: 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 27-30 April 2013; Berlin, Germany
   Google Scholar
• Zurenko G, Bien P, Bensaci M, et al. Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone. Ann Clin Microbiol Antimicrob 2014;13:46
   PubMedGoogle Scholar
• De Vriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006;42(8):1111-17
   PubMed Web of Science ®Google Scholar
• Flanagan S, McKee EE, Das D, et al. Evaluation of the potential of tedizolid and linezolid to affect mitochondrial function using nonclinical and pharmacokinetic assessments. Antimicrob Agents Chemother 2014. [Epub ahead of print]
   Google Scholar
• Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(3):1127-34
   PubMed Web of Science ®Google Scholar
• Putnam SD, Sader HS, Moet GJ, et al. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagn Microbiol Infect Dis 2010;67(4):359-68
   PubMedGoogle Scholar
• Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49(1):195-201
   PubMed Web of Science ®Google Scholar
• Lodise TP, Butterfield JM, Hegde SS, et al. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function. Antimicrob Agents Chemother 2012;56(4):2062-6
   PubMed Web of Science ®Google Scholar
• Goldberg MR, Wong SL, Shaw JP, et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy 2010;30(1):35-42
   PubMedGoogle Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46(11):1683-93
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011;52(1):31-40
   PubMed Web of Science ®Google Scholar
• Ero MP, Harvey NR, Harbert JL, et al. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. J Thromb Thrombolysis 2014;38(2):235-40
   PubMedGoogle Scholar
• Sosio M, Stinchi S, Beltrametti F, et al. The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by nonomuraea species. Chem Biol 2003;10(6):541-9
   PubMedGoogle Scholar
• Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Investig Drugs 2007;16(5):717-33
   PubMed Web of Science ®Google Scholar
• Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 2005;55(Suppl 2):ii15-20
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Bell JM, Sader HS, et al. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother 2009;53(3):1260-3
   PubMed Web of Science ®Google Scholar
• Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011. Diagn Microbiol Infect Dis 2013;75(3):304-7
   PubMed Web of Science ®Google Scholar
• Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004;48(3):940-5
   PubMed Web of Science ®Google Scholar
• Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol 2009;49(4):465-76
   PubMed Web of Science ®Google Scholar
• Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005;55(Suppl 2):ii31-5
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41(10):1407-15
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014;370(23):2169-79
   PubMed Web of Science ®Google Scholar
• Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003;37(10):1298-303
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40(3):374-80
   PubMed Web of Science ®Google Scholar
• Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003;26(5):511-32
   PubMedGoogle Scholar
• Cooper RD, Snyder NJ, Zweifel MJ, et al. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot (Tokyo) 1996;49(6):575-81
   PubMedGoogle Scholar
• Patti GJ, Kim SJ, Yu TY, et al. Vancomycin and oritavancin have different modes of action in Enterococcus faecium. J Mol Biol 2009;392(5):1178-91
   PubMedGoogle Scholar
• Kim SJ, Cegelski L, Stueber D, et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol 2008;377(1):281-93
   PubMedGoogle Scholar
• Belley A, Neesham-Grenon E, McKay G, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother 2009;53(3):918-25
   PubMed Web of Science ®Google Scholar
• Morrissey I, Seifert H, Canton R, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and beta-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother 2013;68(1):164-7
   PubMedGoogle Scholar
• Rubino CM, Van Wart SA, Bhavnani SM, et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 2009;53(10):4422-8
   PubMed Web of Science ®Google Scholar
• Baltch AL, Smith RP, Ritz WJ, Bopp LH. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1998;42(10):2564-8
   PubMedGoogle Scholar
• Sakoulas G, Rose W, Nonejuie P, et al. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2014;58(3):1494-500
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Bayer AS, Pogliano J, et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012;56(2):838-44
   PubMed Web of Science ®Google Scholar
• Hall Snyder A, Werth BJ, Barber KE, et al. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. J Antimicrob Chemother 2014;69(8):2148-54
   PubMed Web of Science ®Google Scholar
• Werth BJ, Barber KE, Tran KN, et al. Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. J Antimicrob Chemother 2014. [Epub ahead of print]
   Google Scholar
• Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011;53(2):158-63
   PubMed Web of Science ®Google Scholar
• Sierra-Hoffman M, Iznaola O, Goodwin M, Mohr J. Combination therapy with ampicillin and daptomycin for treatment of Enterococcus faecalis endocarditis. Antimicrob Agents Chemother 2012;56(11):6064
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Nonejuie P, Nizet V, et al. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother 2013;57(8):4042-5
   PubMedGoogle Scholar
• Piszczek J, Hutchinson J, Partlow E. Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis. J Antimicrob Chemother 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Rice LB, Eliopoulos GM, Moellering RCJr. In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance. Antimicrob Agents Chemother 1989;33(4):470-3
   PubMedGoogle Scholar
• Descourouez JL, Jorgenson MR, Wergin JE, Rose WE. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother 2013;57(3):1518-20
   PubMed Web of Science ®Google Scholar
• Rice LB, Eliopoulos CT, Yao JD, et al. In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model. Diagn Microbiol Infect Dis 1992;15(2):173-6
   PubMedGoogle Scholar
• Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007;2(5):343-4
   PubMedGoogle Scholar
• Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother 2009;43(12):2108-12
   PubMed Web of Science ®Google Scholar
• Jaspan HB, Brothers AW, Campbell AJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 2010;29(4):379-81
   PubMed Web of Science ®Google Scholar